UY31291A1 - A pharmaceutical composition comprising a pyrazole derivative-0-glucoside - Google Patents

A pharmaceutical composition comprising a pyrazole derivative-0-glucoside

Info

Publication number
UY31291A1
UY31291A1 UY31291A UY31291A UY31291A1 UY 31291 A1 UY31291 A1 UY 31291A1 UY 31291 A UY31291 A UY 31291A UY 31291 A UY31291 A UY 31291A UY 31291 A1 UY31291 A1 UY 31291A1
Authority
UY
Uruguay
Prior art keywords
glucoside
pyrazole derivative
pharmaceutical composition
invention relates
diabetes mellitus
Prior art date
Application number
UY31291A
Other languages
Spanish (es)
Inventor
Michael Mark
Klaus Dugi
Leo Thomas
Frank Himmelsbach
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP07114460 priority Critical
Application filed filed Critical
Publication of UY31291A1 publication Critical patent/UY31291A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

La invencion se refiere a una composicion faramcéutica segun la reivindicacion 1, que comprende un derivado de pirazol-O-glucosido. The invention relates to a faramcéutica composition according to claim 1 comprising a pyrazole derivative-O-glucoside. combinado con un inhibidor de DPP IV que es adecuado en el tratamiento o la prevencion de una o más afecciones seleccionadas entre la diabetes mellitus de tipo 1, diabetes mellitus de tipo 2, tolerancia anormal a la glucosa e hiperglucemia. combined with a DPP IV inhibitor which is suitable for the treatment or prevention of one or more conditions selected from diabetes mellitus type 1, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. Además, la presente invencion se refiere a métodos para prevenir o tratar trastornos metabolicos y afecciones relacionadas. Furthermore, the present invention relates to methods for preventing or treating metabolic disorders and related conditions.
UY31291A 2007-08-16 2008-08-14 A pharmaceutical composition comprising a pyrazole derivative-0-glucoside UY31291A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07114460 2007-08-16

Publications (1)

Publication Number Publication Date
UY31291A1 true UY31291A1 (en) 2009-03-31

Family

ID=39828484

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31291A UY31291A1 (en) 2007-08-16 2008-08-14 A pharmaceutical composition comprising a pyrazole derivative-0-glucoside

Country Status (4)

Country Link
PE (1) PE05972009A1 (en)
TW (1) TW200911275A (en)
UY (1) UY31291A1 (en)
WO (1) WO2009022008A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg A process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
DE102005035891A1 (en) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as medicaments
MX2008014024A (en) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Polymorphs.
PE02352011A1 (en) 2006-05-04 2011-04-14 Boehringer Ingelheim Int pharmaceutical combinations comprising metformin and linagliptin
PE09382009A1 (en) 2007-08-16 2009-08-08 Boehringer Ingelheim Int pharmaceutical composition comprising a benzene derivative substituted glucopyranosyl
AR071175A1 (en) 2008-04-03 2010-06-02 Boehringer Ingelheim Int pharmaceutical composition comprising an inhibitor of dipeptidyl peptidase-4 (DPP4) and a companion drug
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "Treatment for diabetes in patients unsuitable for therapy with metformin"
KR20190016601A (en) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
UY32177A (en) * 2008-10-16 2010-05-31 Boehringer Ingelheim Int Treatment of diabetes in patients with insufficient glycemic control despite therapy drug, oral or not, antidiabetic
JP2012512848A (en) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Salt forms of organic compounds
AR074990A1 (en) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Treatment of diabetes in patients with inadequate glycemic control despite metformin therapy
TWI466672B (en) * 2009-01-29 2015-01-01 Boehringer Ingelheim Int Treatment for diabetes in paediatric patients
AP201105794A0 (en) 2009-02-13 2011-08-31 Boehringer Ingelheim Int Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a furtherantidiabetic agent and uses thereof.
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
EP2368552A1 (en) 2010-03-25 2011-09-28 Boehringer Ingelheim Vetmedica GmbH 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal
KR101819609B1 (en) 2010-05-05 2018-01-17 베링거 인겔하임 인터내셔날 게엠베하 Sequential Combination Therapy by the Weight Reducing Treatment Followed by the DPP-4 Inhibitor
MX2012014247A (en) 2010-06-24 2013-01-18 Boehringer Ingelheim Int Diabetes therapy.
AR083878A1 (en) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Vasoprotectives and cardioprotective anti-diabetic therapy, linagliptin, treatment method
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
JP6218811B2 (en) * 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Xanthine derivatives as DPP-4 inhibitors for use in the treatment of SIRS and / or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014161836A1 (en) 2013-04-04 2014-10-09 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
EP3485890A1 (en) 2014-01-23 2019-05-22 Boehringer Ingelheim Vetmedica GmbH Treatment of metabolic disorders in canine animals
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
EP3468562A1 (en) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1500403A4 (en) * 2002-04-26 2008-09-17 Ajinomoto Kk Preventive/remedy for diabetes
EP2060573A3 (en) * 2002-08-21 2011-04-13 Boehringer Ingelheim Pharma GmbH & Co. KG 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as medicine
UY28103A1 (en) * 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma New imidazo-pyridinones substituted, their preparation and their use as medicacmentos
WO2005085246A1 (en) * 2004-02-18 2005-09-15 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthine, the production thereof and the use in the form of a dpp inhibitor
DE102004044221A1 (en) * 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 3-methyl-7-butynyl-xanthine, their production and their use as medicaments
GT200600218A (en) * 2005-06-10 2007-03-28 Formulation and direct compression process
UY29694A1 (en) * 2005-07-28 2007-02-28 Boehringer Ingelheim Int Methods for preventing and treating metabolic disorders and new pyrazole derivatives-o-glucoside
PE02352011A1 (en) * 2006-05-04 2011-04-14 Boehringer Ingelheim Int pharmaceutical combinations comprising metformin and linagliptin
CL2008000133A1 (en) * 2007-01-19 2008-05-23 Boehringer Ingelheim Int pharmaceutical composition comprising a compound derived pyrazole-o-glucoside combined with at least a second therapeutic agent; and use of the composition for the treatment of diabetes mellitus, cataract, neuropathy, myocardial infarction, and

Also Published As

Publication number Publication date
TW200911275A (en) 2009-03-16
WO2009022008A1 (en) 2009-02-19
PE05972009A1 (en) 2009-06-06

Similar Documents

Publication Publication Date Title
BRPI0407620A (en) derivatives of substituted aryl and heteroaryl as modulators of glucose metabolism and their prophylaxis and treatment of disorders
BRPI0916877A2 (en) pharmaceutical composition and administration of the same
UY27666A1 (en) Novel pyridine derivatives and quinoline
TW200918542A (en) Sirtuin modulating compounds
ECSP066972A (en) Mutual Prodrugs of glucosamine and glucosamine / anti-inflammatory compositions and methods
BRPI0606256A2 (en) inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type I, use and pharmaceutical composition comprising the same
TW201014861A (en) Combination therapy for the treatment of diabetes and related conditions
NO333011B1 (en) A pharmaceutical composition for the treatment of blood pressure reduction and diseases caused by blood pressure reduction, kit of parts, commercial package and applications of the combination of composition.
BR0311437A (en) Hot melt TTS for the administration of rotigotine
BRPI0606704A (en) derived from pyridinyl and pyrimidinyl substituted as metabolic modulators and treatment of disorders related to the same
BRPI0511757A (en) derived from aryl and substituted heteroaryl as metabolic modulators and the prophylaxis and treatment of disorders related to this
NO20074824L (en) Extension of time to disease progression or survival in cancer patients
ECSP11010854A (en) Dioxa-bicyclo derivatives [3.2.1] octane-2,3,4-triol
AR061967A1 (en) Acid isopropyl ester 4- [6- (6-methanesulfonyl-2-methyl-pyridin-3-ylamino) -5-methyl-pyrimidin-4-yloxy] -piperidine-i-carboxylic acid, pharmaceutical composition comprising it and a method of preparing the same and use of this compound for the treatment of metabolic disorders
ECSP066279A (en) Aryl and heteroaryl derivatives as modulators of metabolism trisubstituted and prophylaxis and treatment of disorders related thereto
SV2011003954A (en) GPR120 receptor agonists and uses thereof
ECSP099376A (en) Inhibitors of Akt activity
CL2007003352A1 (en) heteromonociclos derivatives of nitrogen compounds; pharmaceutical composition comprising said compound; and use of the compound for the treatment of circulatory diseases, metabolic diseases and / or diseases of the nervous system cen
ECSP088625A (en) Compounds for the treatment of inflammatory disorders
ECSP099618A (en) fused ring compounds as partial agonists of PPAR-gamma
GT201200250A (en) Ariltriazolonas linked to bisaryl and use
CR20170369A (en) COMBINATION OF A AND INSULIN agonist GLP-1 (Divisional 2011-0188)
ECSP10010007A (en) Treatment with alpha-7 ligands selective-
NZ598778A (en) Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions
PA8566101A1 (en) Novel pyridine derivatives and pyrimidine